Nanologica Overview
- Year Founded
-
2004
- Status
-
Public
- Employees
-
72
- Stock Symbol
-
NICA
- Investments
-
2
- Share Price
-
$0.02
- (As of Friday Closing)
Nanologica General Information
Description
Nanologica AB is a Swedish life science tools company that develops, manufactures, and sells key consumables to pharmaceutical manufacturers. Its products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, it can increase productivity and reduce costs for pharmaceutical manufacturers. The group operates in a world-wide niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments.
Contact Information
Website
www.nanologica.comCorporate Office
- Forskargatan 20G
- 151 36 Sodertalje
- Sweden
Corporate Office
- Forskargatan 20G
- 151 36 Sodertalje
- Sweden
Nanologica Stock Performance
As of 13-Nov-2026, Nanologica’s stock price is $0.02. Its current market cap is $5.54M with 329M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.02 | $0.02 | $0.02 - $0.24 | $5.54M | 329M | 731K | $0.04 |
Nanologica Financials Summary
As of 30-Jun-2026, Nanologica has a trailing 12-month revenue of $5.75M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 24,588 | 8,129 | 14,602 | 35,475 |
| Revenue | 5,745 | 2,150 | 1,375 | 136 |
| EBITDA | 4,323 | (3,569) | (4,305) | (5,179) |
| Net Income | 2,066 | (5,220) | (6,206) | (7,071) |
| Total Assets | 25,069 | 9,575 | 12,970 | 7,748 |
| Total Debt | 5,519 | 2,333 | 4,617 | 67 |
Nanologica Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Nanologica Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Nanologica Patents
Nanologica Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2021090013-A1 | New composition comprising amorphous nanoporous silica particles | Inactive | 06-Nov-2019 | ||
| GB-201916122-D0 | New compositions | Inactive | 06-Nov-2019 | ||
| ES-2932081-T3 | Empty porous particles for use in the treatment, prevention and/or retardation of degeneration of neurodegenerative diseases, neurons and glia | Active | 15-Apr-2019 | ||
| CA-3130033-A1 | Empty porous particles for use in treatment, prevention and/or postponement of degeneration of neurodegenerative diseases, neurons and glia | Pending | 15-Apr-2019 | ||
| EP-3894857-A1 | Empty porous particles for use in treatment, prevention and/or postponement of degeneration of neurodegenerative diseases, neurons and glia | Active | 15-Apr-2019 | A61K9/1611 |
Nanologica Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Nanologica Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Nanologica Investments & Acquisitions (2)
Nanologica’s most recent deal was a Merger/Acquisition with Syntagon for . The deal was made on 29-Jan-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Syntagon | 29-Jan-2026 | Merger/Acquisition | Pharmaceuticals | ||
| INIM Pharma | 16-May-2018 | Corporate | Drug Discovery |
Nanologica ESG
Risk Overview
Risk Rating
Updated June, 30, 2023
33.15 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,766
Rank
Percentile
Pharmaceuticals
Industry
of 891
Rank
Percentile
Pharmaceuticals
Subindustry
of 435
Rank
Percentile
Nanologica Exits (1)
Nanologica’s most recent exit was on 16-May-2018 from INIM Pharma. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| INIM Pharma | 16-May-2018 | Completed |
|
Nanologica Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Syntagon | Sodertalje, Sweden | 1998 |
Nanologica FAQs
-
When was Nanologica founded?
Nanologica was founded in 2004.
-
Where is Nanologica headquartered?
Nanologica is headquartered in Sodertalje, Sweden.
-
What is the size of Nanologica?
Nanologica has 72 total employees.
-
What industry is Nanologica in?
Nanologica’s primary industry is Other Pharmaceuticals and Biotechnology.
-
Is Nanologica a private or public company?
Nanologica is a Public company.
-
What is Nanologica’s stock symbol?
The ticker symbol for Nanologica is NICA.
-
What is the current stock price of Nanologica?
As of 13-Nov-2026 the stock price of Nanologica is $0.02.
-
What is the current market cap of Nanologica?
The current market capitalization of Nanologica is $5.54M.
-
What is Nanologica’s current revenue?
The trailing twelve month revenue for Nanologica is $5.75M.
-
What is Nanologica’s annual earnings per share (EPS)?
Nanologica’s EPS for 12 months was $0.04.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
